{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-016666","form_type":"8-K","ticker":"RCKT","cik":"0001281895","company_name":"ROCKET PHARMACEUTICALS, INC.","filed_at":"2024-03-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.675458+00:00","generated_at":"2026-06-04T05:14:03.901529+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Rocket Pharma names Aaron Ondrey CFO; expands leadership team for commercial transition","bullets":["Aaron Ondrey appointed CFO, effective March 25, 2024; previously CFO of Mirati Therapeutics.","Compensation: base salary $485k, target bonus 45%, equity grant ~$2.5M (half options, half RSUs) with 3-year vesting.","Other appointments: Kinnari Patel as President/Head of R&D/COO; Jonathan Schwartz as Chief Medical & Gene Therapy Officer; Mark White as GM Commercial; Martin Wilson as GC/Chief Corporate Officer.","Leadership changes position Rocket for planned commercial stage transition for gene therapies."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-016666","json":"https://secwatch.observer/filing/0001140361-24-016666.json","markdown":"https://secwatch.observer/filing/0001140361-24-016666.md","text":"https://secwatch.observer/filing/0001140361-24-016666.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1281895/000114036124016666/0001140361-24-016666-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1281895/000114036124016666/ef20025500_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T05:14:03.901529+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"27f9f85084","claim":"Aaron Ondrey was appointed as Chief Financial Officer at ROCKET PHARMACEUTICALS, INC..","evidence_excerpt":"On March 25, 2024, Aaron Ondrey was appointed by Rocket Pharmaceuticals, Inc. (the “Company”) as the Company’s Chief Financial Officer and Principal Financial Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1281895/000114036124016666/0001140361-24-016666-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}